ZOMDF (Zomedica) Other Long-Term Liabilities: $0.40 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zomedica Other Long-Term Liabilities?

Zomedica ZOMDF -0.18% Other Long-Term Liabilities is $0.40 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

Zomedica's other long-term liabilities for the quarter that ended in Jun. 2026 was $0.40 Mil.

Zomedica's quarterly other long-term liabilities declined from Dec. 2025 ($0.47 Mil) to Mar. 2026 ($0.42 Mil) and declined from Mar. 2026 ($0.42 Mil) to Jun. 2026 ($0.40 Mil).

Zomedica's annual other long-term liabilities declined from Dec. 2023 ($0.94 Mil) to Dec. 2024 ($0.40 Mil) but then increased from Dec. 2024 ($0.40 Mil) to Dec. 2025 ($0.47 Mil).

Zomedica Other Long-Term Liabilities Related Terms

Zomedica Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Zomedica's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Other Long-Term Liabilities Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 1.88 0.94 0.40 0.47

Zomedica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.47 0.47 0.42 0.40

Zomedica Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.40 Mil mean?
Zomedica (ZOMDF) has a Other Long-Term Liabilities of $0.40 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zomedica and its competitors.
Is Zomedica's Other Long-Term Liabilities too high?
Zomedica's current Other Long-Term Liabilities is $0.40 Mil.
How does Zomedica's Other Long-Term Liabilities compare to SERA and HYPR?
Zomedica's Other Long-Term Liabilities of $0.40 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zomedica and its competitors. Zomedica's current Other Long-Term Liabilities is $0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.08 — trading 53.7% below its estimated fair value. The current Other Long-Term Liabilities is $0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Other Long-Term Liabilities is $0.40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.